30 Spam-Free Article(s) Found
Article Searches
How Do Listed Companies Perform With A U.S. IPO? https://seekingalpha.com/article/4164247-listed-companies-perform-u-s-ipo?source=feed_tag_ipo_analysis Apr 19, 2018 - US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (NASDAQ:MOR) began t
Wall Street Breakfast: Tax Day At The Supreme Court https://seekingalpha.com/article/4163417-wall-street-breakfast-tax-day-supreme-court?source=feed_tag_wall_st_breakfast Apr 17, 2018 - A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to over
Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77% https://seekingalpha.com/article/4162018-big-biotech-swings-2016-ipo-avexis-pops-82-percent-2018-ipo-menlo-drops-77-percent?source=feed_tag_ipo_analysis Apr 10, 2018 - Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs. Betting on a biotech buyout. The billion-dollar biotech buyouts continue. News broke on Monday t
Baker Bros. Advisors Lp Buys Biomarin Pharmaceutical Inc, Ablynx NV, Erytech Pharma, Sells ... http://www.gurufocus.com/news/658331/baker-bros-advisors-lp-buys-biomarin-pharmaceutical-inc-ablynx-nv-erytech-pharma-sells-advanced-accelerator-applications-sa-achaogen-inc-neuroderm Mar 29, 2018 - Baker Bros. Advisors Lp Buys Biomarin Pharmaceutical Inc, Ablynx NV, Erytech Pharma, Sells Advanced Accelerator Applications SA, Achaogen Inc, NeuroDerm, Stocks: BMRN,ARGX,MDGL,SAGE,NBIX,GWPH,ABLX,ERYP,RYTM,NKTR,, release date:Mar 29, 2018
Ablynx NV reports FY results https://seekingalpha.com/news/3333105-ablynx-nv-reports-fy-results?source=feed_news_all Feb 22, 2018 - Ablynx NV (OTCPK:ABLYF): FY Net loss of €108.5MRevenue of €55.5M (-34.9% Y/Y)Press Release
Your Daily Pharma Scoop: AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Celgene Reports Results For Otezla https://seekingalpha.com/article/4148018-daily-pharma-scoop-abbvies-upadacitinib-johnson-and-johnsons-tremfya-celgene-reports-results?source=feed_sector_healthcare Feb 19, 2018 - AbbVie’s promising pipeline. Johnson & Johnson’s Tremfya data promising. Celgene reports positive results in phase 2 trial of Otezla.
BioSci Rounds Report For Feb. 1, 2018 https://seekingalpha.com/article/4142533-biosci-rounds-report-feb-1-2018?source=feed_sector_healthcare Feb 02, 2018 - Novel gene-therapy innovator (Solid Biosciences) continued its rally.With the promising molecule (entinostat), Syndax Pharmaceuticals extended its gain for the month.Recent Sanofi acquisition of Ablyn
Sanofi Scoops Up Ablynx: Start Of A Buyout Spree? https://seekingalpha.com/article/4141515-sanofi-scoops-ablynx-start-buyout-spree?source=feed_sector_healthcare Jan 31, 2018 - On Jan. 29, Sanofi announced it would be acquiring Ablynx; the smaller biotech had previously rebuffed a lower offer from Novo Nordisk.Ablynx shareholders will be rewarded with a solid premium and San
Sanofi (SNY) To Acquire Ablynx (ABLX) - Slideshow https://seekingalpha.com/article/4141289-sanofi-sny-acquire-ablynx-ablx-slideshow?source=feed_sector_healthcare Jan 30, 2018 - The following slide deck was published by Sanofi in conjunction with this event.
U.S. Biotech/Pharma Sector Daily Observations Letter: January 29, 2018 https://seekingalpha.com/article/4141119-u-s-biotech-pharma-sector-daily-observations-letter-january-29-2018?source=feed_all_articles Jan 30, 2018 - Small pullback in S&P 500 but biotech indexes continued the uptrend.Sanofi acquired Ablynx for $4.8B for its nanobody platform.PTC Therapeutics released early intrim data in SMA type 1.More insights o

Pages: 123

Page 1>
DeepLinks for Ablynx NV
ABLX - Google Finance https://www.google.com/finance?q=ABLX Industry related info and international coverage Summary News
ABLX - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=ABLX Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options